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INTRODUCTORY PARAGRAPH 107 
Asthma, hay fever (or allergic rhinitis) and eczema (or atopic dermatitis) often coexist in the same 108 
individuals1, partly because of a shared genetic origin2-4. To identify shared risk variants, we performed 109 
a genome-wide association study (GWAS, n=360,838) of a broad allergic disease phenotype that 110 
considers the presence of any one of these three diseases. We identified 136 independent risk variants 111 
(P<3x10-8), including 88 not previously reported, which implicate 132 nearby genes in allergic disease 112 
pathophysiology. Disease-specific effects were detected for only six variants, confirming that most 113 
represent shared risk factors. Tissue-specific heritability and biological process enrichment analyses 114 
suggest that shared risk variants influence lymphocyte-mediated immunity. Six target genes provide an 115 
opportunity for drug repositioning, while for 36 genes CpG methylation was found to influence 116 
transcription independently of genetic effects. Asthma, hay fever and eczema partly coexist because 117 
they share many genetic risk variants that dysregulate the expression of immune-related genes.118 
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MAIN TEXT 119 
The analytical approach used is summarized in Supplementary Fig. 1. We tested for association with 120 
allergic disease 8,307,659 genetic variants that passed quality control filters (Supplementary Table 1), 121 
comparing 180,129 cases who reported having suffered from asthma and/or hay fever and/or eczema, 122 
and 180,709 controls who reported not suffering from any of these diseases (Supplementary Table 2), 123 
all of European ancestry. Meta-analysis of results from the 13 contributing studies (Supplementary 124 
Fig. 2) identified 99 genomic regions (i.e. loci) located >1 Mb apart containing at least one genetic 125 
variant associated with allergic disease at a genome-wide significance threshold of 3x10-8 (Fig. 1 and 126 
Supplementary Table 3). Based on approximate conditional analysis5, 136 genetic variants in these 99 127 
loci had a statistically independent association with disease risk (Table 1). Henceforth, we refer to 128 
these as “sentinel risk variants”, which either represent, or are in linkage disequilibrium (LD) with, a 129 
causal functional variant. These included 69 (in 35 loci) located <1 Mb from risk variants reported in 130 
previous GWAS of allergic disease (Supplementary Table 4). Of note, 21/69 sentinel variants were in 131 
low linkage disequilibrium (LD, r2<0.05) with the previously reported risk variants, indicating that they 132 
represent novel associations in these loci. The remaining 67 sentinel variants (in 64 loci) were located 133 
>1Mb from previously reported associations (Supplementary Table 5), of which 23 were in low LD 134 
with nearby variants reported for other diseases or traits (Supplementary Table 6). Eighteen loci had 135 
multiple independent association signals (Supplementary Table 3). Altogether, we identified 88 136 
(67+21) genetic associations with allergic disease that are new, a substantial increment over the 75 137 
associations reported previously (Supplementary Fig. 3 and Supplementary Table 7). 138 
 139 
As expected from a study design that maximized power to identify shared risk variants6, we found that 140 
130 of the 136 sentinel variants had similar allele frequencies in case-only association analyses that 141 
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compared three non-overlapping groups of adults: those who reported suffering from asthma only 142 
(n=12,268), hay fever only (n=33,305) or eczema only (n=6,276) (Supplementary Table 8). There was 143 
thus no evidence that these 130 variants have differential effects on the three individual diseases. The 144 
six variants with evidence for stronger effects in one allergic disease when compared to the other two 145 
were located in five known allergy risk loci (e.g. FLG and GSDMB, Fig. 2). On the other hand, many 146 
sentinel variants (26 or 19%) were also associated with the age at which symptoms of any allergic 147 
disease first developed (n=35,972, Supplementary Table 9), the allele associated with a higher disease 148 
risk being always associated with earlier age-of-onset (Supplementary Fig. 4). For 18 of those 26 149 
variants, the effect on age-of-onset was not significantly different between individual diseases 150 
(Supplementary Table 9), suggesting that they influence the age at which symptoms first develop for 151 
all three diseases. 152 
 153 
We then used LD-score regression analysis7 (see Methods) to quantify the liability-scale heritability of 154 
the three individual diseases that was collectively explained by the 136 top associations in the Nord-155 
Trøndelag Health Study (HUNT, up to n=20,350), which was not part of the discovery meta-analysis. 156 
This was found to be 3.2% for asthma, 3.8% for hay fever and 1.2% for eczema, respectively 157 
representing about a fifth, a sixth and a tenth of the overall heritability of each disease that is explained 158 
by common single nucleotide polymorphisms (SNPs; Supplementary Table 10). Therefore, the 159 
inheritance of risk alleles at these loci partly explains why these three conditions coexist. 160 
  161 
To understand the biological consequences of allergy risk variants, we then identified plausible target 162 
genes of the 136 sentinel variants. There were 5,739 transcripts annotated near (+/- 1 Mb) sentinel 163 
variants, including 2,569 protein-coding genes. For 132 of these transcripts, the nearby sentinel variant 164 
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was in high LD (r2≥0.8) with either a non-synonymous SNP (22 genes; Supplementary Table 11) or a 165 
sentinel expression quantitative trait locus (eQTL) identified in relevant tissues or cell types (additional 166 
110 genes; Supplementary Tables 12 and 13). We refer to these 132 transcripts as plausible target 167 
genes, which were located in 54 of the 99 risk loci (Fig. 1 and Supplementary Table 14). Studies that 168 
confirm the target gene predictions and identify the underlying functional variants are warranted; genes 169 
that could be prioritized for functional follow-up include 78 identified using a more conservative LD 170 
threshold (r2≥0.95; Supplementary Table 14) or 61 predicted to be the likely targets based on 171 
independent evidence from publicly available functional data (Supplementary Tables 15 and 16; see 172 
Methods for details). Of note, 77 (58%) of the 132 plausible target genes have not previously been 173 
implicated in allergic disease (Supplementary Tables 14), and so potentially represent novel key 174 
contributors to disease pathophysiology (examples in Table 2).  175 
 176 
Next, based on data from the GTEx consortium8, we identified broad tissue types in which the plausible 177 
target genes were disproportionally expressed, using the Tissue Specific Expression Analysis (TSEA) 178 
approach described previously9. We excluded genes located in the major histocompatibility complex 179 
(MHC) or not present in the TSEA GTEx database, leaving 112 plausible target genes for analysis. 180 
When compared to the remaining 17,671 non-MHC genes in the genome, we found that the list of 181 
plausible targets was enriched for genes specifically expressed in whole-blood and lung (Fig. 2A). Both 182 
associations remained significant (Supplementary Fig. 5) after restricting the background gene list to 183 
the subset of 12,804 non-MHC genes with eQTLs reported in the same studies used to identify the 184 
plausible target genes (Supplementary Tables 12). These results indicate that the plausible targets are 185 
enriched for genes preferentially expressed in whole-blood and lung, and that this is unlikely to arise 186 
because the plausible targets were also enriched for genes with eQTLs in those tissues. 187 
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 188 
The enrichment in whole-blood and lung expression could be a general feature of arbitrary genes 189 
located near the sentinel risk variants. To address this possibility, we determined how often the 190 
enrichment observed with the plausible target genes was exceeded when analyzing 1,000 lists of 191 
random genes. When genes were randomly selected from the same 98 non-MHC allergy risk loci 192 
identified in the meta-analysis, matching on the number of plausible target genes identified per locus 193 
(range 0 to 11) and in total (i.e. 112), the enrichment observed in whole-blood was not exceeded in any 194 
of the 1,000 random lists when considering results for all 25 tissues tested (Fig. 3A and 195 
Supplementary Table 17). Similar results were observed for lung. For comparison, arbitrary genes 196 
were also selected from 2 Mb loci drawn at random from the genome, or simply from all genes in the 197 
genome, and results were very similar (Fig. 3A and Supplementary Table 17). Randomly selecting 198 
genes from the subset with eQTLs also had no impact on the results (Supplementary Fig. 5). 199 
Therefore, we conclude that the enrichment in expression observed in whole-blood and lung was 200 
specific to the genes identified as plausible targets of sentinel risk variants. 201 
 202 
To identify specific cell types that were likely to contribute to the enrichment in whole-blood, we used 203 
an orthogonal approach10 that quantifies tissue-specific enrichments in SNP heritability rather than in 204 
gene expression. Specifically, this approach quantifies the trait heritability that is explained by SNPs 205 
that overlap cell type-specific regulatory annotations measured by the ENCODE project in 100 206 
different cell types. In this analysis, the strongest enrichment in SNP heritability was observed for 207 
regulatory annotations measured in helper T cells (including Th17, Th1 and Th2), regulatory T cells, 208 
CD4+ and CD8+ memory T cells, CD56+ NK cells and CD19+ B cells (Fig. 3B and Supplementary 209 
Table 18). These results are consistent with previous findings11 and the widely documented 210 
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contribution of these T cell subsets to allergic responses. Similar results were obtained after removing 211 
the 136 top associations from our GWAS results (Supplementary Fig. 6 and Supplementary Table 212 
18), indicating that the observed enrichments extend beyond genome-wide significant SNPs. These 213 
results demonstrate that genetic risk variants shared between asthma, hay fever and eczema, including 214 
but not limited to the ones that reached genome-wide significance, operate to a large extent by 215 
modulating gene expression in cells of the immune system.  216 
 217 
To help understand how the sentinel variants might influence immune cell function, we then identified 218 
biological processes over-represented amongst the plausible target genes when compared to the rest of 219 
the genes in the genome (MHC excluded), using GeneNetwork12. As for the analysis of tissue-specific 220 
enrichment in gene expression, for each specific biological process, we compared the enrichment 221 
observed with the list of plausible target genes with that observed with 1,000 gene lists randomly 222 
drawn from the same allergy risk loci. After correcting for the 3,770 biological processes tested, we 223 
found 35 pathways for which the enrichment observed with the plausible target genes was exceeded in 224 
<5% of the random gene lists (Fig. 3C and Supplementary Table 19). These included biological 225 
processes related to T and B cell activation, B cell proliferation and isotype switching, interleukin (IL-) 226 
2 and IL-4 production, confirming a key role for the sentinel variants and the likely target genes on 227 
lymphocyte-mediated immunity. Other noteworthy enrichments were observed for pathways related to 228 
induction of cell death, lipid phosphorylation and NK cell differentiation. 229 
 230 
Consistent with a widespread effect of allergy risk variants on immune cell function, many sentinel risk 231 
variants have been reported to associate with other immune-related traits, notably blood cell counts 232 
(Supplementary Table 20) and auto-immune diseases (Supplementary Table 21). The genetic 233 
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overlap with auto-immune diseases was not restricted to sentinel variants, as evidenced by significant 234 
positive genetic correlations with celiac disease, Crohn's disease and inflammatory bowel disease 235 
obtained after excluding the 136 top associations from our GWAS results (Supplementary Table 22). 236 
Other significant genetic correlations were observed for obesity- and depression-related traits, both 237 
previously suggested by twin studies13. The former provides support for a role of allergy risk variants in 238 
the regulation of metabolic homeostasis. 239 
 240 
We then investigated whether any of the plausible target genes identified could potentially represent a 241 
new opportunity for drug repositioning, as shown by others14. We found that 29 genes have been or are 242 
being considered as drug targets, including nine for the treatment of allergic diseases (Supplementary 243 
Table 23), four for auto-immune diseases (Supplementary Table 24) and 16 for other diseases 244 
(Supplementary Table 25), mostly cancer. Therefore, for 20 genes, drugs currently in development for 245 
other indications might influence biological mechanisms underlying allergic disease. For six of these 246 
genes, the effect on gene expression of the allergy protective allele (Supplementary Table 26) and the 247 
existing drug matched (Table 3), suggesting that the latter might attenuate (and not exacerbate) allergy 248 
symptoms, and so could be prioritized for pre-clinical testing.  249 
 250 
Finally, based on data from the BIOS consortium15 (n=2,101), we found that a substantial fraction of 251 
target genes (36 or 27%) had a nearby CpG site for which methylation levels were significantly 252 
correlated with mRNA levels in blood, independently of SNP effects (Supplementary Table 27). This 253 
observation raises the possibility that environmental effects on the methylation state of these CpGs 254 
might influence target gene expression and, by extension, allergic disease risk. Well powered studies 255 
that address this possibility are warranted. In exploratory analyses, we tested the association between 256 
13 
 
five established risk factors for allergic disease (see Methods) and the methylation state of expression-257 
associated CpGs for those 36 genes  (n=1,211). We observed only one significant association, between 258 
smoking and the methylation state of PITPNM2 (Supplementary Table 28), which was reported in a 259 
previous study16. These results indicate that smoking might influence the risk of allergic disease partly 260 
by modulating the methylation state of expression-associated CpGs for PITPNM2, a PYK2-binding 261 
protein17 potentially involved in granulocyte function18,19.  262 
 263 
In conclusion, we doubled the number of risk variants for allergic disease through a large GWAS of a 264 
multi-disease phenotype defined based on information from three genetically correlated diseases, 265 
asthma, hay fever and eczema. With a few exceptions, the variants identified had similar effects on the 266 
individual disease entities. The risk variants, and their likely target genes, are predicted to influence 267 
overwhelmingly the function of immune cells. Novel drugs for allergy are proposed based on 268 
genomics-guided drug repositioning. Finally, our results raise the possibility that environmental factors 269 
such as smoking might influence allergic disease risk through modulation of target gene methylation.270 
14 
 
ONLINE METHODS 271 
Methods for this paper are provided in a separate file.  272 
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FIGURES 273 
 274 
Figure 1. GWAS meta-analysis identifies 99 loci containing 136 genetic risk variants 275 
independently associated with the risk of allergic disease at P<3x10-8. The 136 sentinel risk variants 276 
were located in 35 previously reported (69 variants) and 64 novel (67 variants) risk loci. The numbers 277 
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of plausible target genes of sentinel risk variants identified for each locus are shown, with target gene 278 
names listed in blue font. For loci with many target genes, only a selection is listed. When no target 279 
gene was identified, the nearest gene(s) to the sentinel variants are instead shown in black font. Red 280 
vertical line in Manhattan plot shows genome-wide significance threshold used (P=3x10-8).  281 
  282 
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 283 
Figure 2. Six of the 136 sentinel variants had significant allele-frequency differences in pairwise 284 
case-only association analyses contrasting individuals suffering from a single allergic disease. For 285 
each sentinel variant, we performed three case-only association analyses, comparing asthma-only cases 286 
(n=12,268) against hay fever-only cases (n=33,305); asthma-only cases against eczema-only cases 287 
(n=6,276); and hay fever-only cases against eczema-only cases. After accounting for multiple testing, 288 
significant associations for at least one of these analyses were only observed for six of the 136 sentinel 289 
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variants, which are shown in the first two rows of the figure. For a given variant, the vertices of the 290 
inner triangle point to the position along the edges of the outer triangle that corresponds to the allele 291 
frequency difference observed between pairs of single-disease cases. For example, the rs61816761:A 292 
allele, which is located in the Fillagrin gene, was 1.32-fold more common in individuals suffering only 293 
from eczema when compared to individuals suffering only from hay fever (P=7.2x10-8), consistent with 294 
this SNP being a stronger risk factor for eczema than for hay fever. A similar result (OR = 1.26, 295 
P=0.0004) was observed for this variant when contrasting eczema-only cases against asthma-only 296 
cases. For comparison, a variant with no allele frequency differences in all three pairwise single-disease 297 
association analyses is also shown (rs2228145, in the IL6R gene). In this case, the three estimated odds 298 
ratios were approximately equal to 1. The color of the OR font reflects the significance of the 299 
association: red for P<1.2x10-4 (correction for multiple testing), blue for P<0.05 and black for P>0.05. 300 
  301 
 302 
  303 
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 (A) 304 
 305 
(B) 306 
 307 
 308 
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(C) 309 
 310 
 311 
Figure 3. Tissues and biological processes influenced by allergy risk variants. 312 
 313 
(A) Enrichment of tissue-specific gene expression in 25 broad tissues studied by the GTEx 314 
consortium. We used the TSEA approach9 to test if genes specifically expressed in a given tissue were 315 
enriched amongst the list of plausible target genes when compared to other genes in the genome. The 316 
enrichment (y-axis) is shown as the -log10 of the Fisher’s exact test P-value. For comparison, we 317 
analyzed 1,000 lists of random genes instead of the plausible target genes. We selected genes at random 318 
using three strategies (see Methods for details). First, genes were randomly drawn from the 98 non-319 
MHC allergy risk loci identified in our GWAS, matching on the number selected per locus and in total. 320 
The enrichment P-value for each of the 1,000 random gene lists is shown by a grey circle. The black-321 
solid line shows the P-value for the 50th most significant random list (i.e. corresponding to the 5th 322 
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percentile): under the null hypothesis of no enrichment, this P-value should be close to 0.05 (horizontal 323 
grey line). Second, genes were drawn at random from 2 Mb loci selected at random from the genome, 324 
matching on the number of genes selected (and available for selection) per locus and in total. Third, 325 
genes were drawn at random from all 18,300 genes available for analysis. For the latter two strategies, 326 
the P-value for the 50th most significant random gene list is shown by the blue and yellow lines, 327 
respectively; enrichment results for each individual random dataset are not shown. Similar results were 328 
obtained after restricting the random genes and the background gene list to the subset of genes with 329 
eQTLs (Supplementary Fig. 6). Genes in the MHC were excluded from these analyses. 330 
.  331 
(B) Enrichment of SNP-based heritability in 220 individual cell type-specific regulatory 332 
annotations. We used stratified LD score regression analysis 10 to quantify the contribution of SNPs 333 
that overlap cell type-specific regulatory annotations to the SNP-based disease heritability. Annotations 334 
with an enrichment in SNP heritability (-log10 of the P-value of the regression coefficient, y-axis) that 335 
was significant after correcting for multiple testing (P<0.0002) are shown in black circles (top 10 listed 336 
in blue font; all results in Supplementary Table 18). SNPs in the MHC were excluded from these 337 
analyses. 338 
 339 
(C) Biological processes enriched amongst the list of plausible target genes. We used 340 
GeneNetwork12 to test if the plausible target genes as a group were more likely to be part of a specific 341 
biological process category when compared to the rest of the genes in the genome. The enrichment (y-342 
axis) is shown as the –log10 of the Wilcoxon rank-sum test P-value (see Methods for details). The top 343 
10 pathways are listed in blue font. For comparison, we analyzed 1,000 random gene lists generated 344 
using the same three strategies described above. For each of these strategies, the P-value for the 50th 345 
22 
 
most significant random gene list is shown by the black (random genes from allergy loci), blue 346 
(random genes from random loci) and yellow (random genes selected from all available genes) lines. 347 
Similar results were obtained after restricting the random genes and the background gene list to the 348 
subset of genes with eQTLs (not shown). Genes in the MHC were excluded from these analyses. 349 
  350 
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TABLES 351 
 352 
Table 1. Main association results for the 136 variants independently associated with the risk of allergic disease at P<3x10-8. 353 
 354 
Locus 
Index 
in 
locus 
Chr Bp SNP EA OA OR SE P-value 
P-value in 
conditional 
analysesa 
Freq Gene context Novelty status 
1 1 1 2510755 rs10910095 G A 1.042 0.0073 2.70E-08 NA 0.84 TNFRSF14-[]-FAM213B NewLocus 
2 1 1 8482078 rs301806 T C 1.048 0.0050 1.77E-20 NA 0.54 [RERE] NewLocus 
3 1 1 25251923 rs760805 T A 1.038 0.0051 6.39E-13 NA 0.58 [RUNX3] NewLocus 
4 1 1 35681738 rs76167968 T C 1.056 0.0093 1.26E-08 NA 0.93 SFPQ-[]-ZMYM4 NewLocus 
5 1 1 150265704 rs7512552 C T 1.031 0.0049 1.43E-09 NA 0.52 C1orf54-[]-MRPS21 
KnownLocus-
KnownVariant 
6 1 1 152285861 rs61816761 A G 1.224 0.0211 7.38E-21 NA 0.01 [FLG] KnownLocus-KnownVariant 
6 2 1 152179152 rs12123821 T C 1.111 0.0124 6.81E-17 4.41E-018 0.05 RPTN-[]-HRNR 
KnownLocus-
KnownVariant 
6 3 1 151796742 rs11204896 C G 1.063 0.0085 2.36E-12 1.18E-010 0.90 [RORC] KnownLocus-NewVariant 
7 1 1 154426970 rs2228145 C A 1.038 0.0050 4.30E-13 NA 0.35 [IL6R] KnownLocus-KnownVariant 
8 1 1 161185058 rs2070901 T G 1.039 0.0056 1.31E-11 NA 0.26 NDUFS2-[]-FCER1G NewLocus 
9 1 1 167431352 rs2988277 C T 1.040 0.0051 4.00E-14 NA 0.66 [CD247] NewLocus 
10 1 1 173146921 rs4090390 A C 1.048 0.0058 1.32E-15 NA 0.22 TNFSF18--[]-TNFSF4 NewLocus 
10 2 1 172700868 rs1102705 G A 1.058 0.0088 3.07E-10 4.20E-011 0.11 FASLG-[]--TNFSF18 NewLocus 
11 1 1 226914734 rs697852 A G 1.041 0.0066 1.58E-09 NA 0.85 [ITPKB] NewLocus 
12 1 2 8442248 rs10174949 G A 1.066 0.0054 7.34E-31 NA 0.68 [LINC00299] KnownLocus-KnownVariant 
13 1 2 64836267 rs4671601 C T 1.039 0.0064 8.79E-09 NA 0.83 [LOC339807] NewLocus 
14 1 2 102941311 rs10865050 G A 1.130 0.0073 6.98E-61 NA 0.85 [IL18R1] KnownLocus-KnownVariant 
14 2 2 102926362 rs12470864 A G 1.057 0.0051 4.23E-26 3.63E-010 0.35 IL1RL2-[]- KnownLocus-
24 
 
IL18R1 KnownVariant 
15 1 2 112388538 rs4848612 A G 1.038 0.0058 2.33E-10 NA 0.76 BCL2L11--[]--ANAPC1 NewLocus 
15 2 2 112269127 rs13403656 A T 1.045 0.0077 2.18E-08 2.84E-008 0.16 BCL2L11--[]--ANAPC1 NewLocus 
16 1 2 113590467 rs1143633 C T 1.034 0.0052 1.65E-10 NA 0.70 [IL1B] NewLocus 
17 1 2 143831599 rs74847330 A G 1.048 0.0076 1.76E-09 NA 0.88 KYNU-[]-ARHGAP15 NewLocus 
18 1 2 198950240 rs1064213 G A 1.035 0.0049 5.37E-12 NA 0.47 [PLCL1] KnownLocus-KnownVariant 
19 1 2 228707862 rs13384448 T C 1.042 0.0058 2.82E-12 NA 0.76 CCL20-[]-DAW1 NewLocus 
20 1 2 234115629 rs1057258 C T 1.045 0.0067 1.39E-10 NA 0.80 [INPP5D] NewLocus 
21 1 2 242698640 rs34290285 G A 1.082 0.0064 4.05E-33 NA 0.73 [D2HGDH] NewLocus 
22 1 3 33069091 rs6776757 G A 1.033 0.0050 3.14E-10 NA 0.47 [GLB1] KnownLocus-KnownVariant 
23 1 3 72394852 rs61192126 T C 1.037 0.0055 8.85E-11 NA 0.69 LINC00870--[]-RYBP NewLocus 
24 1 3 101242751 rs13088318 A G 1.031 0.0053 8.63E-09 NA 0.62 FAM172BP-[]-TRMT10C NewLocus 
25 1 3 121652141 rs75557865 G A 1.029 0.0050 1.63E-08 NA 0.57 [SLC15A2] NewLocus 
26 1 3 141321836 rs10663129 ACT A 1.042 0.0054 1.12E-13 NA 0.33 [RASA2] NewLocus 
27 1 3 188133336 rs60946162 T C 1.041 0.0051 8.57E-15 NA 0.42 [LPP] KnownLocus-KnownVariant 
27 2 3 188402586 rs17607589 C T 1.053 0.0066 1.83E-14 2.50E-015 0.84 [LPP] KnownLocus-NewVariant 
27 3 3 187633268 rs519973 A G 1.034 0.0052 4.50E-10 2.57E-011 0.35 BCL6--[]--LPP-AS2 
KnownLocus-
NewVariant 
27 4 3 187793833 rs2030030 T C 1.041 0.0068 1.01E-08 9.55E-009 0.86 BCL6--[]-LPP-AS2 
KnownLocus-
NewVariant 
28 1 3 196372546 rs80064395 C T 1.070 0.0094 1.55E-12 NA 0.94 FBXO45-[]-CEP19 
KnownLocus-
NewVariant 
29 1 4 4775401 rs10033073 G A 1.040 0.0059 1.19E-10 NA 0.35 STX18--[]-MSX1 NewLocus 
30 1 4 38798648 rs5743618 C A 1.100 0.0058 3.29E-58 NA 0.70 [TLR1] KnownLocus-KnownVariant 
31 1 4 103593898 rs227275 C A 1.034 0.0050 3.69E-11 NA 0.56 [MANBA] NewLocus 
32 1 4 123316076 rs4145717 T G 1.059 0.0052 9.18E-27 NA 0.34 [ADAD1] KnownLocus-
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KnownVariant 
32 2 4 123454110 rs150254607 ATAT A 1.078 0.0097 4.63E-14 2.08E-024 0.07 IL2-[]-IL21 
KnownLocus-
NewVariant 
33 1 5 14610309 rs16903574 G C 1.071 0.0095 1.40E-12 NA 0.08 [FAM105A] NewLocus 
34 1 5 35862841 rs7717955 C T 1.073 0.0055 9.13E-36 NA 0.71 [IL7R] KnownLocus-KnownVariant 
35 1 5 40492655 rs7714574 T C 1.032 0.0050 5.94E-10 NA 0.53 DAB2---[]--PTGER4 
KnownLocus-
KnownVariant 
36 1 5 110470137 rs6594499 C A 1.075 0.0050 4.64E-46 NA 0.48 WDR36-[]-CAMK4 
KnownLocus-
KnownVariant 
36 2 5 110166083 rs6869502 T A 1.079 0.0066 6.38E-29 4.46E-029 0.18 SLC25A46-[]--TSLP 
KnownLocus-
KnownVariant 
36 3 5 110401872 rs1837253 C T 1.070 0.0056 1.63E-31 7.28E-020 0.78 SLC25A46--[]-TSLP 
KnownLocus-
KnownVariant 
36 4 5 110159879 rs1814576 C T 1.121 0.0114 1.41E-22 2.05E-012 0.09 SLC25A46-[]--TSLP 
KnownLocus-
KnownVariant 
37 1 5 118684297 rs250308 T C 1.031 0.0051 3.95E-09 NA 0.37 [TNFAIP8] NewLocus 
38 1 5 131996500 rs848 A C 1.068 0.0063 1.52E-24 NA 0.24 [IL13] KnownLocus-KnownVariant 
38 2 5 131799626 rs3749833 C T 1.039 0.0056 3.30E-11 2.67E-009 0.30 [C5orf56] KnownLocus-NewVariant 
38 3 5 131989136 rs3091307 G A 1.062 0.0062 3.64E-21 4.40E-010 0.20 RAD50-[]-IL13 
KnownLocus-
KnownVariant 
39 1 5 141494934 rs10068717 T C 1.042 0.0052 4.80E-15 NA 0.62 [NDFIP1] NewLocus 
39 2 5 140925362 rs740474 C T 1.034 0.0051 5.62E-11 6.73E-011 0.42 [DIAPH1] NewLocus 
40 1 5 159909345 rs2910162 G A 1.033 0.0053 2.55E-09 NA 0.68 MIR3142-[]-MIR146A NewLocus 
41 1 5 176782218 rs13153019 C T 1.035 0.0059 1.33E-08 NA 0.26 LMAN2-[]-RGS14 NewLocus 
42 1 6 32626403 rs34004019 A G 1.101 0.0062 3.78E-52 NA 0.70 
HLA-DQA1-
[]-HLA-
DQB1 
KnownLocus-
KnownVariant 
42 2 6 31323012 rs2854001 A G 1.059 0.0062 1.18E-19 5.46E-019 0.18 [HLA-B] KnownLocus-KnownVariant 
42 3 6 31351664 rs2507978 G A 1.035 0.0052 1.23E-10 2.43E-015 0.41 HLA-B-[]-MICA 
KnownLocus-
NewVariant 
42 4 6 33647058 rs10947428 C T 1.046 0.0061 3.54E-13 6.45E-015 0.19 [ITPR3] KnownLocus-KnownVariant 
42 5 6 29893575 rs9259819 G T 1.036 0.0058 2.44E-09 3.45E-010 0.50 [HLA-J] KnownLocus-
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NewVariant 
42 6 6 31574525 rs28895016 C T 1.097 0.0113 9.36E-16 2.48E-009 0.91 NCR3-[]-AIF1 
KnownLocus-
KnownVariant 
42 7 6 33046752 rs3097670 G C 1.064 0.0089 7.73E-12 2.02E-008 0.88 [HLA-DPA1] KnownLocus-NewVariant 
43 1 6 90987512 rs2134814 C G 1.046 0.0052 1.65E-17 NA 0.65 [BACH2] NewLocus 
44 1 6 106667535 rs9372120 G T 1.042 0.0062 4.23E-11 NA 0.18 [ATG5] NewLocus 
45 1 6 128294709 rs35469349 A T 1.037 0.0056 2.32E-10 NA 0.26 [PTPRK] NewLocus 
46 1 6 138195151 rs5029937 G T 1.081 0.0136 2.37E-08 NA 0.97 [TNFAIP3] NewLocus 
47 1 6 157419508 rs9383820 C T 1.037 0.0063 1.24E-08 NA 0.76 [ARID1B] NewLocus 
48 1 6 167390671 rs72033857 C 
CC
TT
T 
1.057 0.0090 1.25E-09 NA 0.11 RNASET2-[]-MIR3939 NewLocus 
49 1 7 20560996 rs6461503 T C 1.039 0.0049 1.75E-14 NA 0.53 ITGB8--[]-ABCB5 
KnownLocus-
NewVariant 
49 2 7 20376018 rs10486391 A G 1.030 0.0050 6.82E-09 1.46E-009 0.53 [ITGB8] KnownLocus-NewVariant 
50 1 7 28156887 rs6977955 T C 1.046 0.0061 7.12E-13 NA 0.21 [JAZF1] NewLocus 
51 1 7 50253897 rs17664743 A G 1.042 0.0061 6.22E-11 NA 0.20 C7orf72-[]-IKZF1 NewLocus 
52 1 7 77018542 rs4296977 C T 1.055 0.0071 2.14E-13 NA 0.16 [GSAP] NewLocus 
53 1 8 81292599 rs7824394 A C 1.050 0.0052 3.47E-20 NA 0.37 MIR5708--[]--ZBTB10 
KnownLocus-
KnownVariant 
54 1 8 128814091 rs6990534 A G 1.042 0.0054 6.35E-14 NA 0.36 [MYC] KnownLocus-KnownVariant 
55 1 9 6208030 rs144829310 T G 1.090 0.0068 1.19E-35 NA 0.16 RANBP6--[]-IL33 
KnownLocus-
KnownVariant 
55 2 9 6051399 rs343478 G A 1.033 0.0050 2.59E-10 8.68E-015 0.52 RANBP6-[]--IL33 
KnownLocus-
NewVariant 
55 3 9 5064193 rs16922576 C T 1.036 0.0056 3.22E-10 3.90E-011 0.32 [JAK2] KnownLocus-NewVariant 
56 1 9 123650534 rs10760123 T G 1.032 0.0053 5.23E-09 NA 0.38 PHF19-[]-TRAF1 NewLocus 
57 1 9 131613191 rs12551834 G A 1.058 0.0093 3.02E-09 NA 0.92 C9orf114-[]-LRRC8A NewLocus 
58 1 10 6094697 rs61839660 T C 1.080 0.0085 4.42E-19 NA 0.07 [IL2RA] KnownLocus-KnownVariant 
58 2 10 6074451 rs4747846 C G 1.036 0.0051 1.00E-11 3.69E-009 0.52 [IL2RA] KnownLocus-KnownVariant 
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59 1 10 9049253 rs12413578 C T 1.095 0.0082 1.30E-27 NA 0.90 GATA3---[]---SFTA1P 
KnownLocus-
KnownVariant 
59 2 10 9064361 rs1444789 C T 1.066 0.0064 1.48E-22 5.05E-018 0.20 GATA3---[]---SFTA1P 
KnownLocus-
KnownVariant 
59 3 10 8605553 rs11255753 T G 1.041 0.0056 2.02E-12 6.97E-014 0.26 GATA3--[]SFTA1P 
KnownLocus-
NewVariant 
59 4 10 9032555 rs72782676 C G 1.303 0.0390 3.16E-11 6.29E-012 0.98 GATA3---[]---SFTA1P 
KnownLocus-
NewVariant 
59 5 10 8841669 rs2025758 T C 1.041 0.0050 4.68E-15 9.41E-012 0.58 GATA3---[]---SFTA1P 
KnownLocus-
NewVariant 
59 6 10 8936162 rs11255968 C T 1.090 0.0147 7.74E-09 2.92E-010 0.96 GATA3---[]---SFTA1P 
KnownLocus-
KnownVariant 
60 1 10 64382359 rs2893907 C A 1.031 0.0050 1.84E-09 NA 0.58 [ZNF365] KnownLocus-KnownVariant 
61 1 10 104225832 rs10883723 C T 1.030 0.0052 1.58E-08 NA 0.31 C10orf95-[]-ACTR1A NewLocus 
62 1 11 65551957 rs479844 G A 1.038 0.0050 1.60E-13 NA 0.57 AP5B1-[]-OVOL1 
KnownLocus-
KnownVariant 
63 1 11 76293758 rs7936323 A G 1.088 0.0049 2.24E-63 NA 0.46 WNT11--[]-LRRC32 
KnownLocus-
KnownVariant 
63 2 11 76299431 rs55646091 A G 1.179 0.0122 2.26E-40 4.20E-023 0.05 WNT11--[]-LRRC32 
KnownLocus-
KnownVariant 
63 3 11 76343428 rs11236814 A T 1.068 0.0085 3.98E-14 9.81E-012 0.91 WNT11--[]-LRRC32 
KnownLocus-
NewVariant 
64 1 11 95425526 rs59593577 C T 1.053 0.0075 1.58E-11 NA 0.87 SESN3--[]-FAM76B NewLocus 
65 1 11 111470567 rs7130753 C T 1.045 0.0056 7.05E-15 NA 0.69 LAYN-[]-SIK2 NewLocus 
66 1 11 118743286 rs12365699 G A 1.061 0.0067 5.15E-18 NA 0.85 DDX6-[]-CXCR5 NewLocus 
67 1 11 128158189 rs56129466 A G 1.047 0.0061 1.92E-13 NA 0.79 
KIRREL3-
AS3---[]--
ETS1 
KnownLocus-
KnownVariant 
68 1 12 48196982 rs55726902 G A 1.051 0.0060 2.59E-16 NA 0.80 [HDAC7] NewLocus 
69 1 12 50345671 rs11169225 A T 1.045 0.0064 1.23E-11 NA 0.18 [AQP2] NewLocus 
70 1 12 57489709 rs1059513 T C 1.084 0.0081 1.05E-22 NA 0.89 [STAT6] KnownLocus-KnownVariant 
70 2 12 56401085 rs10876864 G A 1.047 0.0050 1.42E-19 1.99E-019 0.39 SUOX-[]-IKZF4 
KnownLocus-
KnownVariant 
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71 1 12 111932800 rs7137828 T C 1.033 0.0050 2.22E-10 NA 0.54 [ATXN2] NewLocus 
72 1 12 121363724 rs6489785 T C 1.043 0.0051 1.55E-15 NA 0.37 SPPL3-[]-HNF1A-AS1 NewLocus 
73 1 12 123742692 rs63406760 T TG 1.047 0.0062 2.95E-13 NA 0.77 C12orf65-[]-CDK2AP1 NewLocus 
74 1 13 41173408 rs4943794 C G 1.043 0.0061 7.18E-12 NA 0.23 [FOXO1] NewLocus 
75 1 13 73627275 rs9573092 A G 1.030 0.0052 2.67E-08 NA 0.70 PIBF1-[]-KLF5 NewLocus 
76 1 14 35761675 rs1048990 G C 1.039 0.0066 1.04E-08 NA 0.16 [PSMA6] KnownLocus-KnownVariant 
77 1 14 38097001 rs111914382 TG T 1.036 0.0059 8.09E-09 NA 0.27 FOXA1-[]--TTC6 
KnownLocus-
KnownVariant 
78 1 14 68754417 rs2104047 T C 1.042 0.0054 1.64E-13 NA 0.36 [RAD51B] NewLocus 
79 1 14 75968608 rs9323612 A G 1.032 0.0053 8.58E-09 NA 0.70 JDP2-[]-BATF NewLocus 
80 1 14 103235012 rs9989163 A G 1.029 0.0050 1.92E-08 NA 0.49 RCOR1-[]-TRAF3 NewLocus 
81 1 15 41782684 rs12440045 C A 1.033 0.0051 4.89E-10 NA 0.55 RTF1-[]-ITPKA NewLocus 
82 1 15 61068347 rs10519067 G A 1.055 0.0073 9.32E-13 NA 0.86 [RORA] NewLocus 
83 1 15 67448363 rs56375023 A G 1.073 0.0059 8.24E-32 NA 0.21 [SMAD3] KnownLocus-KnownVariant 
84 1 15 91045408 rs3540 G A 1.036 0.0053 3.32E-11 NA 0.65 [IQGAP1] NewLocus 
85 1 16 11277358 rs11644510 C T 1.072 0.0053 6.11E-38 NA 0.64 CLEC16A-[]-RMI2 
KnownLocus-
KnownVariant 
85 2 16 11491007 rs12596613 C G 1.032 0.0054 6.06E-09 2.53E-009 0.67 RMI2-[]--LITAF 
KnownLocus-
KnownVariant 
86 1 17 4521473 rs71368508 C A 1.124 0.0191 2.02E-09 NA 0.99 SMTNL2-[]-ALOX15 NewLocus 
87 1 17 38069076 rs921650 A G 1.059 0.0049 5.67E-30 NA 0.48 [GSDMB] KnownLocus-KnownVariant 
87 2 17 38764524 rs112401631 A T 1.260 0.0213 2.20E-26 3.74E-026 0.01 CCR7-[]-SMARCE1 
KnownLocus-
NewVariant 
87 3 17 38770641 rs11464691 TA T 1.052 0.0052 1.37E-21 3.05E-020 0.57 CCR7-[]-SMARCE1 
KnownLocus-
NewVariant 
87 4 17 38149033 rs11652139 A G 1.051 0.0051 7.54E-22 1.70E-008 0.59 [PSMD3] KnownLocus-KnownVariant 
88 1 17 40414862 rs7207591 A G 1.038 0.0060 1.43E-09 NA 0.76 [STAT5B] NewLocus 
89 1 17 43430696 rs7214661 G A 1.032 0.0054 1.20E-08 NA 0.32 MAP3K14-[]- NewLocus 
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ARHGAP27 
90 1 17 47398070 rs9889262 A T 1.043 0.0051 9.65E-16 NA 0.35 [ZNF652] NewLocus 
91 1 18 52336175 rs4801001 T C 1.031 0.0051 5.91E-09 NA 0.42 DYNAP-[]--RAB27B NewLocus 
92 1 18 60009814 rs4574025 T C 1.030 0.0050 6.79E-09 NA 0.56 [TNFRSF11A] NewLocus 
93 1 19 33721455 rs10414065 C T 1.098 0.0106 6.10E-18 NA 0.92 SLC7A10-[]-CEBPA NewLocus 
94 1 20 50157837 rs3787184 A G 1.049 0.0066 1.06E-12 NA 0.78 [NFATC2] KnownLocus-KnownVariant 
95 1 20 52208356 rs2766678 G A 1.057 0.0063 5.04E-18 NA 0.21 [ZNF217] KnownLocus-NewVariant 
96 1 20 62322699 rs6011033 G A 1.047 0.0060 3.50E-14 NA 0.78 [RTEL1] KnownLocus-KnownVariant 
97 1 21 36467830 rs73205303 A G 1.044 0.0069 7.90E-10 NA 0.13 [RUNX1] NewLocus 
98 1 21 44846426 rs76081789 T C 1.065 0.0108 1.34E-08 NA 0.94 [SIK1] NewLocus 
99 1 22 41816652 rs5758343 A T 1.048 0.0061 4.75E-14 NA 0.22 TEF-[]-TOB2 NewLocus 
              
 355 
EA: effect allele. OA: other allele. Freq: Effect allele frequency in Europeans populations of the 1000 Genomes Project. 356 
 357 
a Eighteen loci were found to have multiple independent associations in approximate conditional analyses. We studied these 18 loci in greater 358 
detail using data from the UK Biobank (132,702 unrelated individuals of European descent) to confirm these results. Specifically, for each of 359 
these 18 loci, we tested if the independent variants identified in the GWAS meta-analysis were associated with disease risk when included 360 
simultaneously in a logistic regression model, using R (e.g. glm( disease ~ rs61816761 + rs12123821 + rs11204896 + covariates)). For 17 of 361 
the 18 loci, all sentinel SNPs were independently associated with disease risk at P<0.05 (not shown). The exception was locus #36, for 362 
which one of the 4 sentinel SNPs (rs6594499) had a P=0.12. Therefore, despite the reduced sample size, results from this analysis in the UK 363 
Biobank study confirm that all but one of the independent variants identified by approximate conditional analysis in these 18 loci have a 364 
statistically independent association with disease risk.  365 
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Table 2. Selected examples of plausible target genes not previously implicated in the pathophysiology of allergic disease. 366 
Gene Summary Possible role(s) in allergic diseasea 
RERE Nuclear receptor coregulator that positively regulates retinoic 
acid signaling 
Positive regulation of B cell differentiation, eosinophil survival and 
migration 
PPP2R3C Sub-unit of protein phosphatase 2A (PP2A) that regulates 
immune cell function 
Th2 differentiation, Treg function, response to viral infection 
RASA2 GTPase-activating protein of Ras that regulates receptor signal 
transduction 
Unknown. RASA3: hematopoiesis. RASA4: macrophage 
phagocytosis. 
SIK2 Salt-inducible kinase Regulation of macrophage inflammatory phenotype, metabolic 
homeostasis 
RTF1 Component of the PAF complex, that is involved in 
transcriptional regulation 
Anti-viral response, regulation of TNF expression 
SMARCE1 Sub-unit of the BAF chromatin remodeling complex Repressor of CD4 differentiation 
DYNAP Dynactin-associated protein that activates protein kinase B Cytokine signaling, T cell function 
THEM4 Mithocondrial thioesterase that is a negative regulator of protein 
kinase B 
Vitamin D-dependent macrophage-mediated inflammation 
ARHGAP15 Rho GTPase activating protein that down-regulates RAC1  Rac1-dependent inflammatory response 
SENP7 Sentrin/small ubiquitin-like modifier (SUMO)-specific protease  Susceptibility to viral infection 
SLC15A2 Peptide transporter expressed in skin, nasal and lung epithelial 
cells 
Bacterial peptide recognition and immune activation 
a References that support the possible role(s) listed are cited in the Supplementary Information.  367 
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Table 3. Plausible target genes with drugs in development for indications other than allergic diseases, for which the effect on gene 368 
expression of the allergy protective allele and the existing drug matched.          369 
Plausible 
target  
gene 
Effect of 
allergy 
protective 
allele on 
gene 
expression 
Drug 
Action Drug Status Drug Name Originator Company Active Indications 
CD86 Increased Agonist Discovery BR-02001 Boryung_Pharm_Co_Ltd Autoimmune_disease 
CCR7 Decreased Antagonist Discovery anti-CCR7_chimeric_IgG1_antibodies North_Coast_Biologics_LLC Unidentified_indication 
CCR7 Decreased Antagonist Discovery anti-CCR7_monoclonal_antibody Pepscan_Systems_BV Cancer 
CCR7 Decreased Antagonist Discovery CCR7-targeting_antibody Abilita_Bio_Inc Metastatic_breast_cancer 
CCR7 Decreased Antagonist NA chemokine_antagonists Neurocrine_Biosciences_Inc NA 
CCR7 Decreased Antagonist NA chemokine_receptor_inhibitors Sosei_Group_Corp NA 
F11R Decreased Antagonist Discovery F11R_inhibitors Provid_Pharmaceuticals_Inc Cardiovascular_disease 
F11R Decreased Antagonist Discovery F-50073 Pierre_Fabre_SA Cancer 
PHF5A Decreased Antagonist Discovery PHF5A_inhibitors Fred_Hutchinson_Cancer_Research_Center Glioblastoma 
RGS14 Decreased Antagonist NA regulator_of_G-protein_signaling_14_inhibitor University_of_Malaga Memory loss 
TARS2 Decreased Antagonist Discovery borrelidin Scripps_Research_Institute Infectious_disease 
 370 
 371 
 372 
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Shared genetic origin of asthma, hay fever and eczema  1 
elucidates allergic disease biology 2 
 3 
ONLINE METHODS  4 
2 
 
List of risk variants reported to be associated with allergic disease in previous GWAS 5 
We downloaded the full NHGRI-EBI GWAS catalog database 1 on January 19, 2017 (v1.0.1). We then 6 
identified SNP associations with a P≤5x10-8 and that were reported for an allergic condition, 7 
specifically for which the “MAPPED_TRAIT” variable included the terms “allergic rhinitis”, “allergic 8 
sensitization”, “allergy”, “asthma”, “eczema” and “atopic march”. Excluded associations were 9 
inspected to ensure that no relevant variants were missed by this filtering approach. After excluding 10 
two variants without a reference SNP (rs) ID (both in the MHC), there were 169 associations, including 11 
144 unique rs IDs.  We then used the --clump procedure in PLINK 2 and genotype data from 12 
individuals of European descent from the 1000 Genomes Project 3 (n=294, release 20130502_v5a) to 13 
reduce this list of 144 SNPs to variants in low linkage disequilibrium (LD) with each other (r2<0.05), 14 
which are likely to represent statistically independent associations with allergic disease. After 15 
excluding five variants that were not polymorphic in Europeans (rs7212938, rs62176107, rs17218161, 16 
rs10056340, rs9273349), we identified 75 variants in low LD with each other. We then identified the 17 
earliest GWAS to report an association with each of these 75 variants (or with a SNP with r2>0.05 with 18 
it) and used the year of publication to generate Supplementary Fig. 2.  19 
 20 
Meta-analysis of allergic disease GWAS results conducted in 13 studies (n=360,838) 21 
In each of 13 participating studies (Supplementary Tables 1 and 2), a GWAS was performed using an 22 
additive genetic model in individuals of European descent that reported suffering from asthma and/or 23 
hay fever and/or eczema (case-group, total n=180,129), against those who never reported suffering 24 
from any of these three conditions (control group, total n=180,709). A detailed description of the 25 
procedures used to identify cases and controls, as well as for SNP genotyping, imputation and 26 
association testing, is provided for each study in the Supplementary Information.   27 
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 Prior to the meta-analysis, standard quality control (QC) filters were applied to results from 28 
individual studies (Supplementary Table 1). After QC, and restricting the analysis to SNPs present in 29 
at least the two largest studies (UK Biobank and 23andMe, combined n=256,623), results were 30 
available for 8,307,659 variants, of which most (89%) were available in >95% of the overall sample 31 
size. Intercept estimates from LD score regression analysis 4, which reflect inflation of test statistics 32 
that are likely due to technical biases, ranged between 1.00 and 1.16 (Supplementary Table 1). Results 33 
from individual studies were adjusted for the observed inflation by multiplying the square of the 34 
standard error of each genetic effect estimate by the respective LD score regression intercept. We then 35 
used METAL 5 to combine association results across studies using an inverse-variance-weighted, fixed-36 
effects meta-analysis. P-values from the meta-analysis were further adjusted for the meta-analysis LD 37 
score regression intercept of 1.04. The genome-wide significance threshold was set at 3x10-8, as 38 
suggested previously for GWAS analyzing variants with MAF≥1% 6. 39 
 40 
Identification of independent associations through approximate conditional analyses  41 
For each chromosome, we identified all SNPs with a P≤3x10-8, sorted these based on base pair 42 
position, and then grouped variants into the same locus if the distance between consecutive variants 43 
was <1Mb. Variants located >1 Mb from the previous genome-wide significant variant were assigned 44 
to a new locus. Next, for each of these loci, we identified statistically independent associations using 45 
approximate conditional analyses, as implemented in GCTA 7. We refer to these as sentinel risk 46 
variants. In these analyses, LD calculations were based on a subset of 5,000 individuals from the 47 
UKBiobank study. Briefly, for each locus, we (1) identified the most significantly-associated SNP [i]; 48 
(2) adjusted the summary statistics of all SNPs in that locus by the effect of that top SNP; (3) identified 49 
the most significantly-associated SNP [j] that remained genome-wide significant in that locus; (4) 50 
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adjusted the summary statistics of all SNPs in that locus by the effects of SNPs i and j. We repeated this 51 
process until there were no SNPs associated with allergic disease at P≤3x10-8  after adjusting for the 52 
effect of other, more strongly independently associated variants in that locus. Lastly, we estimated the 53 
LD between sentinel variants located in different risk loci (i.e. >1 Mb apart) and confirmed that the r2 54 
was always close to 0 (no pairs of sentinel variants with r2>0.02).  55 
 56 
Determining the novelty status of independent SNP associations with allergic disease 57 
Previous GWAS identified 144 SNPs associated with the risk of various allergic conditions, which we 58 
grouped into 75 independent associations based on the LD between variants (see above). We used that 59 
information to classify each of our independent SNP associations into two major groups: located in 60 
known (<1Mb from any of those 144 previously reported associations; “KnownLocus”) or new (>1Mb 61 
from those variants; “NewLocus”) allergy risk loci. For the first group, we then estimated the LD 62 
between each sentinel variant identified in our study and all variant(s) reported in previous GWAS. If 63 
all reported variants had an r2<0.05 with our sentinel variant, then our association was considered to 64 
represent a new risk variant in a known risk locus (“KnownLocus-NewVariant”). Alternatively, when at 65 
least one reported variant had an r2≥0.05, our association was considered to be a known risk variant in 66 
a known risk locus (“KnownLocus-KnownVariant”). The second major group of variants were located 67 
in new allergy risk loci. Within this group, we used the same approach just described to determine if 68 
our associations were novel when considering any disease or trait with genome-wide significant 69 
associations reported in the NHGRI-EBI GWAS catalog. 70 
 71 
Comparison of risk allele frequencies between individuals suffering from a single allergic disease 72 
By combining information from asthma, hay fever and eczema in the case-control definition used in 73 
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our GWAS, we expected our study design to improve power to identify risk variants shared between, 74 
but not specific to any of, the three diseases 8. To understand if the associations discovered in our 75 
GWAS were indeed likely to represent risk factors shared across allergic diseases, we took advantage 76 
of the observation that not all affected individuals report allergic co-morbidities 9-11, and compared 77 
allele frequencies between three groups of adults: asthma-only cases (n=12,268), hay fever-only cases 78 
(n=33,305) and eczema-only cases (n=6,276). The studies that contributed to this analysis are indicated 79 
in Supplementary Table 1 and described in detail in the Supplementary Information. We performed 80 
three sets of association analyses contrasting three non-overlapping groups of individuals: asthma-only 81 
(g1) vs. hay fever-only (g2); asthma-only (g1) vs. eczema-only (g3); and hay fever-only (g2) vs. 82 
eczema-only (g3). These analyses are statistically independent from the case-control analysis carried 83 
out as part of the GWAS, which facilitates interpretation of the results. For a given sentinel SNP, results 84 
from these analyses indicate if the risk allele is more (odds ratio [OR] >1) or less (OR<1) common in 85 
e.g. group 1 (g1) when compared to group 2 (g2). For example, if a SNP contributed similarly to the 86 
risks of asthma and hay fever but not eczema, then one would expect an OR~1 in the asthma-only vs. 87 
hay fever-only comparison, but an OR>1 in the asthma vs. eczema and hay fever vs. eczema analyses. 88 
The significance threshold for these analyses was set at 1.2x10-4, which corresponds to a Bonferroni 89 
correction for the 136 SNPs and three sets of analyses performed (i.e. P<0.05/(136x3)). 90 
 91 
Association between sentinel risk variants and variation in allergy age-of-onset 92 
There is considerable variation in the age allergic diseases are first reported, and this has been shown to 93 
be influenced by genetic risk factors 12. We therefore studied the association between the sentinel 94 
variants identified in our GWAS and age-of-onset observed in the UK Biobank study (n=35,972). For 95 
each individual, we first considered the earliest age of any allergic disease (asthma or hay 96 
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fever/eczema; the latter two were covered by the same question, and so could not be differentiated) 97 
being reported. SNPs were tested for association with this phenotype, with sex and a SNP array 98 
variable included as covariates. The significance threshold used for this analysis was 3.6x10-4 (i.e. 99 
P<0.05/136). Because significant SNP associations with this broad age-of-onset phenotype could be 100 
driven by different risk allele frequencies amongst cases suffering from different individual conditions 101 
(for example, a FLG variant might be associated with earliest age-of-onset because it is more prevalent 102 
in eczema cases, which tends to precede the development of asthma and hay fever 13), we repeated the 103 
analysis by considering individuals who had reported suffering only from a single disease: asthma-only 104 
(n=7,445), hay fever-only (n=4,232) and eczema-only (n=1,225). For a given SNP, differences in effect 105 
size (beta) between groups were quantified using the formula z = sigma / SE_sigma, where sigma = 106 
beta_groupA – beta_groupB, and SE_sigma = sqrt(SE_beta_groupA^2 + SE_beta_groupB^2), which 107 
follows a normal distribution. 108 
 109 
Estimating the contribution of the sentinel variants to the heritability of asthma, hay fever and 110 
eczema 111 
Five steps were involved. First, we performed a GWAS of the individual diseases in the HUNT study, 112 
which was not included in the discovery meta-analysis. The HUNT study is described in greater detail 113 
in the Supplementary Information. Briefly, based on self-reported questionnaire information, we 114 
identified 1,875 cases and 16,463 controls for the asthma GWAS; 6,939 cases and 12,844 controls for 115 
the hay fever GWAS; and 2,630 cases and 16,131 controls for the eczema GWAS. After quality control 116 
filters, we analyzed 7.6 million common variants (genotyped and imputed) for association with each 117 
individual phenotype. The genomic inflation factor (i.e. lambda) for these analyses were 1.049 for 118 
asthma, 1.078 for hay fever, and 1.041 for eczema. Second, for each of the three diseases, we 119 
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quantified the overall SNP-based heritabilities with LD score regression 4 using a subset of 1.2 million 120 
HapMap SNPs. To obtain a heritability estimate on the liability scale, we set the population prevalence 121 
to be the same as the sample prevalence, given that this was a population-based study. Third, we 122 
removed the 136 sentinel variants (and all correlated variants, r2>0.05) from the individual disease 123 
GWAS results.  Fourth, we re-estimated SNP-based heritabilities as described for step two, but now 124 
using the GWAS results without the 136 top associations. In the fifth and final step, the contribution of 125 
the 136 sentinel variants towards the heritability of each disease was calculated as the difference 126 
between the SNP-based heritability estimated in steps two (all SNPs) and four (without 136 top 127 
associations).  128 
 129 
Identification of plausible target genes of sentinel risk variants 130 
Two independent strategies were used to identify plausible target genes underlying the observed 131 
associations. By 'target gene' we mean a gene for which protein sequence and/or variation in 132 
transcription is associated with a sentinel risk variant or one of its proxies (r2>0.8).  133 
First, we used wANNOVAR 14 to identify genes containing non-synonymous SNPs amongst all 134 
variants in LD (r2>0.8) with any sentinel risk variant. SNPs in LD with sentinel risk variants were 135 
identified using genotype data from individuals of European descent from the 1000 Genomes Project 3 136 
(n=294, release 20130502_v5a).  137 
 Second, to identify genes with transcription levels associated with a sentinel risk variant or one 138 
of its proxies (r2>0.8), we queried publicly available results from 39 published expression quantitative 139 
trait loci (eQTL) studies conducted in 19 tissues or cell types relevant to allergic disease 140 
(Supplementary Table 12). We used a conservative significance threshold to identify significant SNP-141 
gene expression associations, specifically a P<2.3x10-9 for cis effects (<1 Mb). We selected this 142 
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threshold based on a Bonferroni correction that considers the total number of protein-coding genes (G) 143 
and the number of SNPs likely to have been tested per gene (M): P<0.05/(GxM). G was set at 21,742, 144 
based on the GeneCards database15, queried on October 19th, 2016. We approximate M to be 1,000, as 145 
indicated by others 16-18, and so the threshold becomes P=0.05/(21,472 genes x 1,000 SNPs per 146 
gene)=2.3x10-9. We did not use information from trans eQTLs to identify plausible target genes of 147 
sentinel risk variants, because often these are thought to involve indirect effects19 (e.g. sentinel SNP 148 
influences the expression of a transcript in cis, which in turn affects the expression of many other genes 149 
in trans). 150 
For each eQTL study, and within each study for each tissue, we created a list of SNPs associated 151 
with gene expression in cis at a P<2.3x10-9. Then, for each gene in that study-tissue dataset, we used 152 
the --clump procedure in PLINK to reduced the list of expression-associated SNPs (which often 153 
included many correlated SNPs) to a set of ‘sentinel eQTLs’, defined as the SNPs with strongest 154 
association with gene expression and in low LD (r2<0.05, LD window of 2 Mb) with each other. This 155 
procedure was repeated for each of the 94 study-tissue datasets listed in Supplementary Table 12. 156 
Finally, we identified as a likely target of a sentinel allergy risk variant any gene for which a sentinel 157 
eQTL in any of the 94 study-tissue datasets had an LD r2>0.8 with the sentinel risk variant. That is, we 158 
only considered genes for which there was strong LD between a sentinel variant and a sentinel eQTL, 159 
which reduces the chance of spurious co-localization. We did not use statistical approaches developed 160 
to distinguish co-localization from shared genetic effects because these have very limited resolution at 161 
high LD levels (r2>0.8) 20.  162 
 To help prioritize plausible target genes for functional validation in subsequent studies, we 163 
identified genes for which publicly available functional data supported not just the presence of 164 
chromatin interactions between an enhancer and a gene promoter (based on 5C21, promoter capture Hi-165 
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C22, ChIA-PET23 or in situ Hi-C24 data), but also an association between variation in enhancer 166 
epigenetic marks and variation in gene transcription levels (based on PreSTIGE25, H3K27ac enhancer 167 
and super-enhancer annotation 26, IM-PET27 or FANTOM528 analyses). We considered data from 168 
immune cell types, lung and skin (Supplementary Table 15) and putative enhancers that overlapped a 169 
sentinel risk variant (or one of its strongly correlated proxies, r2>0.95).  170 
 To identify genes that were unlikely to have been previously implicated in the pathophysiology 171 
of allergic disease, we performed the following PubMed query on May 19th, 2017: (asthma OR rhinitis 172 
OR eczema OR atopic OR dermatitis OR allergy OR allergi* OR hayfever OR "hay fever") AND 173 
(gene1 OR gene2 OR … OR gene244). The gene symbols approved by the HUGO Gene Nomenclature 174 
Committee (HGNC) for each of the target genes were inserted into the second part of that query. The 175 
search results were downloaded as an .xml file and the number of unique articles (based on PMID) 176 
listing a given gene symbol was counted using in-house scripts (results in Supplementary Table 14). 177 
To identify genes likely to have been implicated in immune-related processes, we repeated this 178 
approach but replaced the first part of the PubMed query with (immune OR immuni* OR immunol*). 179 
  180 
Enrichment in tissue-specific gene expression 181 
We used the TSEA approach 29 to identify tissues that were likely to be affected functionally by the 182 
biological effects of the sentinel risk variants. We implemented this approach locally using custom 183 
scripts. Specifically, for each of 25 broad tissue types studied by the GTEx consortium, we tested if 184 
genes with tissue-specific expression (based on a Specificity Index threshold 29 [pSI] of 0.05; listed in 185 
file TableS3_NAR_Dougherty_Tissue_gene_pSI_v3-1.txt, downloaded from 186 
http://genetics.wustl.edu/jdlab/psi_package/) were enriched amongst the list of plausible target genes, 187 
when compared to the rest of the genes in the genome. After excluding genes without a pSI value and 188 
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in the MHC, there were 112 plausible target genes and 17,671 background genes available for analysis. 189 
To test if the plausible target genes were enriched for genes with specific expression in a given tissue, 190 
we used Fisher’s exact test (one-sided).  To rule out the possibility that a significant enrichment could 191 
arise because the list of plausible targets was enriched for genes with eQTLs, we repeated the analysis 192 
after restricting the background gene list to a subset of 12,804 genes that were found to have eQTLs in 193 
the same eQTL studies that were used to identify plausible target genes of sentinel variants.  194 
We also tested if a significant enrichment in tissue-specific expression could be a general 195 
feature of genes near sentinel risk variants, and not specific to the list of genes identified as plausible 196 
targets. To address this possibility, we generated 1,000 arbitrary gene lists, each containing 112 random 197 
genes instead of the plausible target genes. We selected genes at random from the 17,783 with an 198 
available pSI value and not in the MHC, using three strategies. First, genes were randomly drawn from 199 
allergy risk loci (+/- 1 Mb of a sentinel variant). To generate each list of random genes, for each non-200 
MHC allergy risk locus L, we randomly selected a locus R from the subset of non-MHC allergy risk 201 
loci for which the number of genes available for selection was the same or greater than the actual 202 
number of plausible target genes (T) selected for that locus L. Then, for that locus R, we selected T 203 
genes at random from the available genes in that locus. This procedure was repeated for all non-MHC 204 
allergy risk loci, ensuring that the same locus was not selected twice in a given random dataset.  205 
In the second strategy, genes were randomly drawn from 2 Mb loci selected at random from the 206 
genome. In this case, to generate each list of random genes, we first partitioned the autosomes 207 
(excluding the MHC) into 1,430 consecutive 2 Mb loci, and counted how many genes with an available 208 
pSI value were present in each of these loci. Then, for each non-MHC allergy risk locus L, we 209 
randomly selected a locus R from the subset of 2 Mb loci for which the number of genes available for 210 
selection satisfied the following criteria: (1) was the same or greater than the actual number of plausible 211 
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target genes (T) selected for that locus L; and (2) matched (within 10%) the number of genes available 212 
for selection for that locus L. This was important to ensure that the randomly selected locus R was 213 
comparable to the allergy risk locus L in terms of the number of genes available for selection. Then, for 214 
that locus R, we selected T genes at random from the available genes in that locus. 215 
In the third and final strategy, we simply selected genes at random from all 17,783 non-MHC 216 
genes with an available pSI value, ignoring where the genes were located in the genome. As a result, 217 
for a given random list, the genes selected could only be in close proximity to other genes in that same 218 
list by chance alone.  219 
The same approach used to test the enrichment in tissue-specific expression for the plausible 220 
target genes was then used to analyze each of the 1,000 lists of random genes. For each of these lists, 221 
the smallest P-value observed across all 25 tissues tested was retained (Pmin). The proportion of random 222 
gene lists (out of 1,000) with a Pmin that was the same or lower than the enrichment P-value observed 223 
with the plausible target genes (Pobs) was then calculated. This corresponds to the probability of 224 
exceeding that enrichment when analyzing the random gene lists, after correcting for the 25 tissues 225 
tested. As we did for the analysis of the plausible target genes, we repeated the generation and analysis 226 
of random gene lists after restricting the genes available for selection (and the background gene list) to 227 
the subset of genes with a known eQTL. 228 
 229 
Enrichment in tissue-specific SNP heritability 230 
Finucane et al. 30 developed an approach to identify tissues likely affected by the functional effects of 231 
disease risk variants, called stratified LD score regression. This approach quantifies the contribution of 232 
SNPs located in tissue-specific regulatory annotations to the overall disease heritability. As such, it 233 
does not require the identification of likely target genes of allergy risk variant and considers all SNPs in 234 
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the genome, not just those with a genome-wide significant association with disease risk. Specifically, 235 
up to four histone marks (H3K4e1, H3K4me3, H3K9ac and H3K27ac) measured by the ENCODE 236 
project are used to define regulatory annotations (e.g. enhancers) in 100 different cell types. SNPs that 237 
overlap these regulatory annotations are then identified and their contribution as a group to the disease 238 
heritability quantified. As recommended by Finucane et al. 30, we ranked cell types based on the P-239 
value of the regression coefficient, rather than the P-value of total enrichment. To ensure that 240 
significant SNP heritability enrichments were not explained by the effects of sentinel variants, we 241 
removed the top SNPs (and any variants with r2>0.05 with these) from the meta-analysis GWAS results 242 
and repeated the LD score regression analysis.  243 
 244 
Enrichment of biological processes 245 
To identify biological processes enriched amongst the non-MHC target genes, we used GeneNetwork 246 
31. With this approach, gene sets originally included in a given GO biological process (BP) were 247 
expanded to include other genes based on a 'guilt-by-association' procedure 31.  After excluding BPs 248 
with <10 or >500 genes, 3,770 BPs were available for analysis. For each BP, we tested its enrichment 249 
amongst the list of plausible target genes as follows. First, we downloaded a gene set file containing z-250 
scores for each of 19,976 unique genes in the genome from 251 
http://129.125.135.180:8080/GeneNetwork/resources/ontology?ontology=GO_BP&term=[pathway], 252 
where ‘pathway’ was replaced with the actual name of the BP being tested (e.g. “GO:0000002”). The z-253 
score for gene X in that file reflects the probability that gene X is part of that BP. Second, we compared 254 
the distribution of z-scores between the list of plausible target genes (107 non-MHC genes were in the 255 
GeneNetwork gene set files, and so were available for analysis) and a background gene list of 18,193 256 
genes (obtained after excluding MHC genes, the 107 plausible target genes and genes not listed in 257 
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GENCODE release 19), using a one-sided Wilcoxon rank-sum test. The P-value from this test 258 
represents the probability that genes in that BP are enriched amongst the list of plausible target genes, 259 
when compared to the background gene list.  260 
 As for the enrichment analysis of tissue-specific expression, we estimated how often a BP 261 
enrichment observed with the list of plausible target genes would be expected had we sampled genes at 262 
random from the allergy risk loci or from random loci. This analysis addresses the possibility that an 263 
observed enrichment might not be a specific feature of the plausible target genes identified but instead 264 
a general feature of genes located near sentinel allergy risk variants, or simply in close proximity to 265 
each other. We used the same three strategies described above to generate 1,000 random gene lists, 266 
sampling from the 18,300 non-MHC with an available z-score and in GENCODE release 19. To 267 
determine if using eQTL information to identify plausible target genes could have biased the 268 
enrichment analysis, we generated and analysed random gene lists after restricting the genes available 269 
for selection to the subset with known eQTLs (12,913), but found very similar results (not shown). 270 
 271 
Common traits and diseases associated with allergic disease risk variants 272 
We first identified all variants in LD (r2>0.8) with a sentinel risk variant using data from Europeans of 273 
the 1000 Genomes Project 3 (n=294, release 20130502_v5a), and extracted any associations with these 274 
reported in the NHGRI-EBI GWAS catalog database 1  (queried on December 13, 2016) or by Astle et 275 
al. 32, a large GWAS of blood cell counts (n=173,480). To complement this analysis, we estimated the 276 
SNP-based genetic correlation between our GWAS and results reported for 229 common traits or 277 
diseases, using LD Hub 33. In these analyses, results from our meta-analysis were not corrected for the 278 
LD score intercept, either at the study level or after the meta-analysis. 279 
 280 
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Identification of target genes with drugs considered as drug targets for human diseases 281 
To identify genes that encode transcripts that are targets of drugs considered for clinical development, 282 
we queried the Thomson Reuters CortellisTM Drug database between November 7 and 15, 2016, which 283 
included 63,417 drugs. The drug search was carried out individually for each gene. First, a search query 284 
was built based on the following format: HGNC approved gene name OR alias_1 OR … OR alias_N. 285 
Gene name aliases were obtained from the Bioconductor annotation package org.Hs.eg.db. For 286 
example, to find drugs that target IL6R, the search query used was: "CD126" OR "IL-6R-1" OR "IL-287 
6RA" OR "IL6Q" OR "IL6RA" OR "IL6RQ" OR "gp80" OR "IL6R" OR "interleukin 6 receptor". 288 
Second, after running the search query, results were filtered based on the ascribed “Target-based 289 
Actions”, keeping only entries that corresponded to the gene name or an alias. For example, of the 65 290 
results obtained with the IL6R query above, only for 20 did the target-based action mention IL6R or an 291 
alias. Third, drug results were downloaded, and the gene and respective drug allocated to one of three 292 
groups: (1) gene with at least one drug considered for the treatment of allergic diseases (15 genes); (2) 293 
gene considered for the treatment of immune-related conditions, but not allergic diseases specifically (8 294 
genes); and (3) gene considered for the treatment of other conditions (26 genes). 295 
 296 
Directional effect of the allergy protective allele on target gene expression 297 
In an attempt to predict if existing drugs would be expected to attenuate or exacerbate allergic 298 
symptoms, we compared the effect on gene expression between the allergy protective allele and the 299 
existing drug. We acknowledge that this is a simplistic comparison, because it assumes that the 300 
directional effect of the protective allele is not tissue- or context-dependent, which is true for most but 301 
not all expression-associated SNPs 34-36.  302 
To determine if the allergy protective allele of a sentinel variant was associated with higher or 303 
15 
 
lower target gene expression, we focused on the subset of target genes identified via an eQTL (see 304 
above). This was straightforward to assess when the sentinel SNP and the expression-associated SNP 305 
were the same variant: for example, if the allergy-protective allele had a negative effect (e.g. beta or z-306 
score) on gene expression in the published eQTL study, then that allele was associated with lower gene 307 
expression. On the other hand, when the two SNPs did not correspond to the same variant, but were in 308 
high LD (r2>0.8) with each other, we first determined which allele of the expression-associated SNP 309 
was on the same haplotype as the allergy-risk allele. Then we used that allele to infer the direction of 310 
effect of the allergy-risk allele on gene expression.  311 
 312 
Modulation of target gene methylation by environmental risk factors 313 
We first tested if variation in DNA CpG methylation was associated with variation in target gene 314 
expression, independently of SNP effects, using data from the Biobank-based Integrative Omics Study 315 
(BIOS) consortium that is described in detail elsewhere 37,38. Methylation and expression levels in 316 
whole-blood samples (n=2,101) were quantified respectively with Illumina Infinium 317 
HumanMethylation450 BeadChip Kit arrays and RNA-seq (2x50bp paired-end, Hiseq2000, >15M read 318 
pairs per sample). For each target gene, we identified CpG sites in cis (<250 Kb from gene) for which 319 
methylation levels were significantly associated with gene expression levels (FDR<5%), after adjusting 320 
the methylation levels for methyation-associated SNPs and expression levels for expression-associated 321 
SNPs. Such CpG sites, called cis-eQTMs, were identified in a previous study 37 and downloaded from 322 
http://genenetwork.nl/biosqtlbrowser. For most genes, there were multiple cis-eQTMs, and so we 323 
selected the CpG site most strongly associated with variation in gene expression for downstream 324 
analyses.  325 
 Next, we tested the association between methylation levels at these sentinel CpGs with five 326 
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established risk factors for allergic disease using data from unrelated individuals of the Netherlands 327 
Twin Register (NTR) study, which was included in the BIOS consortium studies 37,38. The risk factors 328 
tested were current smoking (n=1,221), maternal smoking (n=637), BMI (n=1,214), birth weight 329 
(n=1,015) and number of older siblings (n=775). Information on BMI and current smoking was 330 
collected as part of the NTR biobank project 39 at blood draw. Birth weight was obtained in multiple 331 
NTR surveys as previously described 40. Maternal smoking during pregnancy was measured in NTR 332 
Survey 10 (data collection in 2013) with the following question: Did your mother ever smoke during 333 
pregnancy? with answer categories: no, yes, I don’t know. Information on the number of older siblings 334 
was obtained through self-report in NTR surveys 2, 3 and 6. For twin pairs, the answers were checked 335 
for consistency and missing data for one twin were supplemented with data from the co-twin where 336 
possible. Linear or logistic regression was used to test the association between methylation (β-value) 337 
and individual risk factors, with the following variables included as covariates: sex, age at blood 338 
sampling, methylation array row, bisulphite plate and white blood cell percentages (% neutrophils, % 339 
monocytes, and % eosinophils). The association with maternal smoking was tested while also adjusting 340 
for smoking status.  341 
 342 
Data availability 343 
Summary statistics of the meta-analysis without the 23andMe study will be made publicly available at 344 
the time of publication. The full GWAS summary statistics for the 23andMe discovery data set will be 345 
made available through 23andMe to qualified researchers under an agreement with 23andMe that 346 
protects the privacy of the 23andMe participants. Please contact David Hinds (dhinds@23andme.com) 347 
for more information and to apply to access the data.  348 
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